ReviewJournal of the European Academy of Dermatology and Venereology : JEADV2018
Immune response patterns in non-communicable inflammatory skin diseases.
Review in Journal of the European Academy of Dermatology and Venereology : JEADV, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Tissue and systemic inflammation in dystrophic epidermolysis bullosa: a systematic review and meta-analysis.Orphanet journal of rare diseases · 2025Pooled it
- Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Pooled it
- MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.Frontiers in immunology · 2026Trial
- A phase IIb single-center study to assess the efficacy of apremilast for the treatment of nummular eczema.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Trial
- Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies.Pharmacology research & perspectives · 2024Trial
- Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026Review
- The role of inflammatory cell death in type 1 dominant inflammatory skin diseases.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- Review
- Extracellular serine availability regulates inflammatory skin phenotypes.Biology direct · 2026Article
- Seasonal variation in immune-related adverse events in advanced cancer patients.Cancer immunology, immunotherapy : CII · 2026Article
- Spatial characterization of skin lesions in discoid and systemic lupus erythematosus.Nature communications · 2026Article
- Advanced delivery of natural bioactive compounds for atopic dermatitis: a review of polymeric conjugates and nanocarriers.Natural products and bioprospecting · 2026Review
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases.Frontiers in medicine · 2026Article
- Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation.Nature communications · 2025Article
- The Enigma of Paradoxical Reactions to Biological Therapies.Indian dermatology online journal · 2025Article
- Esophageal Lichen Planus-Contemporary Insights and Emerging Trends.Biomedicines · 2025Review
- The Translational Dermatology Initiative: Aiming at a New Disease Classification of Inflammatory Skin Diseases.JID innovations : skin science from molecules to population health · 2025Article
- Dupilumab, a Novel Treatment for Peripheral Neuropathy: A Case Series.Dermatology and therapy · 2025Article
- Inflammatory Skin Diseases: The Importance of Immunological Signatures.Deutsches Arzteblatt international · 2025Review
- Eosinophilic and Mixed-Cell Infiltration in Odontogenic Cutaneous Sinus Tracts of a Dog.Veterinary medicine and science · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-communicable inflammatory skin diseases (ncISD) such as psoriasis or atopic eczema are a major cause of global disease burden. Due to their impact and complexity, ncISD represent a major challenge of modern medicine. Dermatology textbooks describe more than 100 different ncISD based on clinical phenotype and histological architecture. In the last decades, this historical description was complemented by increasing molecular knowledge - and this knowledge is now being translated into specific therapeutics. Combining the enormous advances made in lymphocyte immunology and molecular genetics with clinical and histological phenotyping reveals six immune response patterns of the skin - type I immune cells cause the lichenoid pattern characterized by immune-mediated cell death of keratinocytes; type II immune cells underlie the eczematous pattern with impaired epidermal barrier, infection and eosinophils as well as the bullous pattern with loss of epithelial integrity; Th17 cells and ILC3 mediate the psoriatic pattern characterized by acanthosis, high metabolic activity and neutrophils; dysbalance of regulatory T cells causes either the fibrogenic pattern with rarefication of cells and dermal thickening or the granulomatous pattern defined by formation of granulomas. With more and more specific therapeutic agents approved, classifying ncISD also according to their immune response pattern will become highly relevant. This review defines the six immune response patterns of ncISD and highlights therapeutic strategies targeting key lymphocyte mediators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.